Equillium, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Equillium, a $7.1M market-cap biotech, reported Q2 2026 cash of $57.2M (vs. $61.3M in Q1 2026) and projects runway into 2029. The lead candidate EQ504 Phase 1 proof-of-mechanism study in Australia is expected to initiate Q4 2026 with topline data ~6 months thereafter. Net loss for Q2 was $4.7M (improved from $5.7M in Q2 2025); R&D expense declined to $2.8M from $4.1M year-over-year.
Why this rating
Cash position ($57.2M) is 8× market cap—critical for survival and clinical execution. Phase 1 initiation is clinical inflection. Runway to 2029 reduces near-term funding risk materially for this micro-cap.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.